Ocular Therapeutix (NASDAQ:OCUL) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $21.00 price target on the stock.
Ocular Therapeutix (NASDAQ:OCUL) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $20.00 price target on the stock.
Ocular Therapeutix (NASDAQ:OCUL) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Ocular Therapeutix™ Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI™ in Wet AMD
Ocular Therapeutix (OCUL) Valuation After Accelerated AXPAXLI NDA Plan in Wet AMD [Yahoo! Finance]